Latest papers

Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.

TAK-778 enhances osteoblast differentiation of human bone marrow cells.

TAK-778 enhances osteoblast differentiation of human bone marrow cells cultured on titanium.

Histamine, dithiaden and human polymorphonuclear leukocytes in vitro.

Effect of H1-antagonist Dithiaden on human PMN-leukocyte aggregation and chemiluminescence is stimulus-dependent.

Highly sensitive liquid chromatography-tandem mass spectrometry method for quantification of a new bone anabolic agent, TAK-778, in human serum.

Enhancement of osteogenesis in vitro by a novel osteoblast differentiation-promoting compound, TAK-778, partly through the expression of Msx2.

Reactive oxygen metabolite production is inhibited by histamine and H1-antagonist dithiaden in human PMN leukocytes.

Effect of KW-7158, a putative afferent nerve inhibitor, on bladder and vesico-vascular reflexes in rats.

Application of 1-alkylamines to a liquid chromatographic/turbo ionspray tandem mass spectrometric method for quantifying metabolites of a new bone anabolic agent, TAK-778, in human serum.

Cationic amphiphilic drugs and platelet phospholipase A(2) (cPLA(2)).

Sustained-release microcapsules of a bone formation stimulant, TAK-778, for local injection into a fracture site.

Bone bonding in bioactive glass ceramics combined with a new synthesized agent TAK-778.

Bone bonding in sintered hydroxyapatite combined with a new synthesized agent, TAK-778.

Cytotoxic activity of benzothiepins against human oral tumor cell lines.

Enhancement of fracture repair in rats with streptozotocin-induced diabetes by a single injection of biodegradable microcapsules containing a bone formation stimulant, TAK-778.

Effects of anticancer drugs, metals and antioxidants on cytotoxic activity of benzothiepins/benzoxepins.

A one-step enzyme-linked immunosorbent assay for a novel osteoblast differentiation-promoting compound, TAK-778 in serum.

Nonreceptor interactions in the pharmacology of blood platelets.

Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778.